December 13th 2018EP. 1: The Advent of Oral Oncolytics and Patient Access
December 13th 2018EP. 2: Multidisciplinary Approach to Managing Oral Oncolytics
December 13th 2018EP. 3: Roles of the Oncologist Versus Pharmacist
December 13th 2018EP. 4: The Efficacy and Safety of CDK4/6 Inhibitors
December 13th 2018EP. 5: Practical Challenges in Switching to CDK4/6 Inhibitors
December 13th 2018EP. 6: Medically Integrated Dispensing Service Best Practices
December 13th 2018EP. 7: Oral Oncolytics and Patient Adherence
December 13th 2018EP. 8: Medically Integrated Pharmacy Teams Spur Innovations
December 13th 2018EP. 9: CDK4/6 Inhibitors in Metastatic Breast Cancer
December 13th 2018EP. 10: Considerations for Treating Patients with CDK4/6 Inhibitors
December 13th 2018EP. 11: Multidisciplinary Care in Breast Cancer
December 13th 2018EP. 12: Best Practices for Managing Patients on CDK4/6 Inhibitors
December 13th 2018EP. 13: Educating Patients and Staff on Using CDK4/6 Inhibitors
December 13th 2018EP. 14: Improving Care for Patients With Metastatic Breast Cancer
December 13th 2018EP. 15: Metastatic Breast Cancer: CDK4/6 Inhibitors
December 13th 2018EP. 16: Benefits and Challenges of CDK4/6 Inhibitors
December 13th 2018EP. 17: Patients' Perspectives on CDK4/6 Inhibitors
December 13th 2018EP. 18: Multidisciplinary Approach: Managing CDK4/6 Inhibitors
December 13th 2018EP. 19: Dispensing of CDK4/6 Inhibitors
December 13th 2018EP. 20: Patient Management of CDK4/6 Inhibitors
December 13th 2018EP. 21: Adherence With CDK4/6 Inhibitors
